- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/54 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
Patent holdings for IPC class C07D 231/54
Total number of patents in this class: 299
10-year publication summary
|
23
|
24
|
36
|
26
|
14
|
17
|
21
|
7
|
9
|
8
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Arena Pharmaceuticals, Inc. | 344 |
21 |
| Gilead Sciences, Inc. | 2220 |
15 |
| Reata Pharmaceuticals, Inc. | 116 |
13 |
| Novartis AG | 10263 |
7 |
| Bristol-myers Squibb Company | 4729 |
7 |
| Bayer Pharma AG | 1014 |
6 |
| Taro Pharmaceuticals Inc. | 15 |
6 |
| Merck Sharp & Dohme LLC | 3735 |
6 |
| Janssen Pharmaceutica N.V. | 3171 |
5 |
| Abbvie Inc. | 1836 |
5 |
| Array BioPharma Inc. | 447 |
5 |
| Boehringer Ingelheim International GmbH | 4493 |
4 |
| Pfizer Inc. | 3384 |
4 |
| Merck Patent GmbH | 5725 |
4 |
| Duke University | 3184 |
4 |
| Bioardis, LLC | 32 |
4 |
| Glaxo Group Limited | 4370 |
3 |
| F. Hoffmann-La Roche AG | 7836 |
3 |
| Takeda Pharmaceutical Company Limited | 2715 |
3 |
| AnaMar AB | 14 |
3 |
| Other owners | 171 |